BiomX (NYSEAMERICAN:PHGE) Director Sells $2,250,000.00 in Stock

BiomX Inc. (NYSEAMERICAN:PHGE) Director Reuven Yeganeh sold 450,000 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $5.00, for a total transaction of $2,250,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Reuven Yeganeh also recently made the following trade(s):

• On Tuesday, March 17th, Reuven Yeganeh sold 530,000 shares of BiomX stock. The shares were sold at an average price of $5.00, for a total transaction of $2,650,000.00.

BiomX Stock Performance

NYSEAMERICAN:PHGE opened at $4.89 on Friday. The firm has a market cap of $7.78 million, a P/E ratio of -0.19 and a beta of 1.68. BiomX Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $14.71. The firm has a 50-day simple moving average of $5.03 and a two-hundred day simple moving average of $6.31.

BiomX (NYSEAMERICAN:PHGE) last issued its earnings results on Thursday, February 19th. The company reported $6.99 earnings per share (EPS) for the quarter. On average, equities research analysts predict that BiomX Inc. will post -2.77 EPS for the current year.

Hedge Funds Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Citadel Advisors LLC purchased a new stake in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX as of its most recent SEC filing. Institutional investors own 40.57% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright downgraded BiomX from a “buy” rating to a “hold” rating in a research note on Monday, March 9th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $26.00.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.